The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•9 June 2026•

2 min read

RBC Capital Upgrades Pfizer on Obesity Drug Progress and FDA Approval

Key Facts

1RBC Capital upgraded Pfizer's rating from Underperform to Sector Perform with the stock priced at $25.70.

2Pfizer received FDA approval for expanded use of its drug HYMPAVZI for hemophilia A or B.

3Pfizer is partnering with Amneal Pharmaceuticals for manufacturing and supply support of its GLP-1 obesity therapies.

Reflecting a shift in sentiment toward the company's drug pipeline, RBC Capital upgraded Pfizer's rating from Underperform to Sector Perform with the stock priced at $25.70. This upgrade follows the U.S. FDA's approval for the expanded use of HYMPAVZI in treating hemophilia A and B. Additionally, Pfizer has strengthened its footprint in the high-growth obesity market through a manufacturing partnership with Amneal Pharmaceuticals for its GLP-1 therapies.

These regulatory and strategic wins come as Pfizer pivots away from its pandemic-era portfolio to compete in the weight-loss sector currently led by Eli Lilly and Novo Nordisk. Per market data, peers like Eli Lilly (LLY) have seen significant valuation premiums due to GLP-1 dominance, a gap Pfizer aims to close via its new manufacturing scale. Analysts suggest the partnership with Amneal is a critical step in de-risking the supply chain for its oral obesity candidates.

Pfizer (PFE) closed at $26.21 on June 12, 2026, after reaching a daily high of $26.49. Investors should watch for upcoming clinical data readouts for berobenatide as the primary catalyst for further re-rating. According to the economic calendar, there are no major sector-specific catalysts in the next week, leaving the stock to trade on technical levels and broader market sentiment following this rating change.